@misc{oai:repo.qst.go.jp:00071091,
 author = {Andou, Kiyoshi and Obayashi, Shigeru and Nagai, Yuji and Oh-Nishi, Arata and Suhara, Tetsuya and et.al and 安東 潔 and 大林 茂 and 永井 裕司 and 大西 新 and 須原 哲也},
 month = {Nov},
 note = {The MPTP-treated common marmoset monkey is a valid Parkinson's disease model. By using this model, preclinical evaluations of therapeutic drugs was sensitively performed by using the activity count of marmosets in their individual living cages as a measure of immobility, one of the major parkinsonian syndrome. Marmosets are easy to use and similar marmosets in terms of strains, ages, body weights, experimental histories, etc. are easier to arrange for the evaluation than in the case of macaque monkeys. The body size of the common marmoset is almost equivalent to that of the big rat but the marmoset brain is bigger than that of the rat. In the MPTP-treated marmoset parkinsonian model, the same MPTP administration regime produced different degrees of parkinsonism across marmosets. The purpose of the present study was to examine the cause of individual differences of the manifestation of parkinsonism in relation with brain neural degeneration. MPTP at 2 mg/kg, s.c. for 2 or 3 consecutive days was given to drug-naive marmosets 3 times with interval of several months. Activity of marmosets in their individual living cages was recorded continuously on each day before and after MPTP administration for these several months. In addition, parkinsonism was visually observed and recorded as dysfunction scores including tremor etc. All marmosets received MPTP showed continued attenuation of activity and increased dysfunction score points with individual difference. The brains of these marmosets were analyzed by microPET (Siemens) using ligands for dopamine transporter ([11C]PE2I) for examining degeneration of dopamine neural damages. The high correlation between the degrees of behavioral manifestations (decreased activity and increased score) and decreased binding potential of the ligand at the striatum was observed. In the present study, it was demonstrated that the degree of behavioral manifestation caused by MPTP was closely related to the degree of dopamine neural damage at the striatum by in vivo PET measurement. The present method in combination of behavioral observation and PET analysis may be important significance in the evaluations of not only neuroprotective actions of new drugs but also of new therapies in the field of preclinical regenerative medicine., 38th Annual Meeting of Society for Neuroscience},
 title = {In vivo PET analysis of parkinsonian marmoset brains},
 year = {2008}
}